Biotech IPOs Roar Back, With Nvidia-Backed Iambic Next in Line
Biotech IPOs rebound in 2026 as Nvidia-backed Iambic Therapeutics files to go public, highlighting AI drug discovery, clinical-stage pipelines and investor trends.
BiopharmaTrend Pro
Strategic signals from the techbio frontier
Editorial analysis of the companies, technologies and deals moving AI drug discovery, longevity, genomics and clinical development — while they still matter. A new deep dive every week, plus premium news, interviews and case studies.
€8.99 / month · €89.90 / year
VAT included. Annual saves 16% — two months free. Cancel any time.
Popular deep dives
A new deep dive publishes each week and joins the archive. Everything below, and everything before it, is open from the day you subscribe.
The Bigger Point Beyond Insilico's Aging Research Milestone
Insilico Medicine’s rentosertib trial suggests aging biomarkers can be prospectively measured in conventional disease trials, opening a potential framework for longevity research.
Could Anthropic Disrupt the Techbio Companies Built for Pharma/Biotech?
Could Anthropic disrupt TechBio? See where general AI models rival domain-specific tools, what makes a real data moat, and which companies face pressure.
Is the Future of AI Drug Discovery Hybrid?
Is AI drug discovery going hybrid? How co-folding models and free energy perturbation complement each other, plus companies to watch like SandboxAQ and Iambic.
Is “Rescuing Failed Drugs with AI” a Category Now?
Is AI drug rescue a new category? See how Biossil, Lantern Pharma, Pathos AI and BPGbio revive failed drugs by finding the patient subgroups that respond.
Membership also covers
Premium news and briefs, interviews with the people building this industry, case studies, and the full two-year archive of everything above.
Who cites our editorial reports
Our reports and analysis have been cited in policy documents, industry studies and peer-reviewed publications by organisations including:
RAND Corporation
AI and chemical & biological weapons riskThe World Bank
Venture capital in Latin AmericaEuropean Parliament
COVID-19 impacts on EU industriesGovernment of India
Study on the CRO sectorNat. Research Foundation, Singapore
AI for Science 2025Nature Reviews Drug Discovery
Medicinal chemistry synthetic toolboxDeloitte
The Future of Biopharma; four reportsMerck Group
SYNTHIA retrosynthesis softwareMIT Sloan
The Promise of Targeted InnovationImperial College London
UK Biopharmaceutical Sector 2024Ernst & Young
Human-machine hybrid economyElsevier
Accelerated drug developmentIFPMA
50 Years of Global Health ProgressForbes · C&EN · GEN
AI in drug discovery coverageWho this is for
R&D and discovery
Track which computational approaches are validated, which are marketing, and which companies have data behind their claims.
Business development
Company landscapes with funding, partnerships and pipeline stage — assembled before you need them, not after a deal lands.
Corporate strategy
Where capital, regulation and technology are moving across AI drug discovery, longevity, genomics and trial design.
Vendors and investors
Who the competition is, what they actually ship, and how buyers in pharma are evaluating the category.
Membership
Full access to every deep dive, the complete archive, and everything published from here on.
Monthly
€8.99 / month
VAT included. Cancel any time.
- A new deep dive every week
- The full two-year archive
- Premium news, interviews and case studies
- Invoice in your member area
Annual
€89.90 / year
VAT included. Save 16% — two months free.
- A new deep dive every week
- The full two-year archive
- Premium news, interviews and case studies
- Invoice in your member area
- Price locked for the year
Questions
What you get
What exactly is a deep dive?
A long-form editorial report, typically 2,000–5,000 words, on one area of the techbio frontier. Each maps the companies working in it, what they have demonstrated so far, the funding and partnerships behind them, and where the evidence is thin. Sourced and linked throughout.
How often do new ones appear?
A new deep dive publishes every week, and joins the archive permanently. Everything published during your membership is included, along with the full back catalogue.
Is it only deep dives?
No. Membership opens all our premium content — deep dives, premium news and briefs, interviews with people building this industry, and case studies.
How is this different from the free newsletter?
The weekly Where Tech Meets Bio newsletter covers what happened. Membership is where we work out what it means — the company landscapes, the technical comparisons and the judgement calls that take weeks to assemble.
Access and billing
How do I get access?
Once you subscribe you get a member area, where you manage your plan and access everything across our editorial and analytical products.
Do I get an invoice?
Yes. A receipt arrives by email after payment, and every invoice is available in your member area — for expensing or procurement.
My card was declined. Can I pay by wire transfer?
Yes. Contact us and we will send instructions for a bank transfer.
Does it renew automatically?
Yes, monthly or annually. We email a reminder before each renewal, and you can switch off automatic renewal at any time from your member area.
Can I cancel easily?
Yes, at any time from your member area. Access continues to the end of the period you have paid for.
Can my team subscribe together?
Get in touch and we will arrange group access and a single invoice.
Start reading
Two months free on the annual plan. Cancel whenever you like.